All In Biotech

Drug Trial Radar · NCT01050829

Gadobutrol Magnevist-controlled Body Study

A Multi-center/Multi-national, Randomized, Controlled, Single-blind, Group Comparison Phase 3 Study to Determine the Efficacy and Safety of Gadobutrol 1.0 Molar in Comparison to Magnevist Following Single Injection in Patients Referred for Contrast-enhanced MRI of the Body/Extremities Regions (Breast, Heart, Abdomen, Kidney, Pelvis, or Extremities)

Last checked: Nov 20, 2026Latest source record: Dec 30, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 370 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

370

Actual

Start

Jan 2010

Primary completion

Apr 2011

Study completion Apr 2011

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Jan 15, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Diagnostic
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to look at the safety (what are the side effects) and efficacy (how well does it work) of gadobutrol when used for taking MR images of the body/extremities regions. The results of the MRI with gadobutrol injection will be compared to the results of MR images taken without contrast and with the results of the MR images taken with Magnevist.

Conditions

  • Magnetic Resonance Imaging

Interventions

  • Gadobutrol (Gadovist, BAY86-4875)Drug

    Single administration at a dose of 0.1 mmol/kg

  • Gadopentetate Dimeglumine (Magnevist, BAY86-4882)Drug

    Single administration at a dose of 0.1 mmol/kg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The total score of the following 3 visualization parameters is used for primary variable: Degree of contrast enhancement; Border delineation; Internal morphology.Time frame: At Day 0

Locations

15 sites in 3 countries. Site status is shown where the registry gives one.

  • Site not named

    Beijing, China

  • Site not named

    Shanghai, China

  • Site not named

    Shanghai, China

  • Site not named

    Nanjing, Jiangsu, China

  • Site not named

    Suzhou, Jiangsu, China

  • Site not named

    Xi’an, Shanxi, China

  • Site not named

    Kamogawa, Chiba, Japan

  • Site not named

    Matsuyama, Ehime, Japan

  • Site not named

    Chikushino-shi, Fukuoka, Japan

  • Site not named

    Fukuoka, Fukuoka, Japan

  • Site not named

    Kobe, Hyōgo, Japan

  • Site not named

    Sunto, Shizuoka, Japan

  • Site not named

    Bunkyo-ku, Tokyo, Japan

  • Site not named

    Seoul, South Korea

  • Site not named

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.